Finanztrends
Deine Einschätzung
Syndax Pharmaceuticals Inc Aktie
Heute zeigt Syndax Pharmaceuticals Inc einen mittleren Kursanstieg von 2,13 %.
Die Syndax Pharmaceuticals Inc Aktie wird von der Community positiv bewertet, besonders das Thema Lohnenswerte Investition für die nächsten Jahre sticht hervor.
Was spricht für und gegen Syndax Pharmaceuticals Inc in den nächsten Jahren?
Pro
?
M************
?
A****************
?
U****************
Kontra
?
W******* i* V********
?
M****
?
L*********** I********** f** d** n******* J****
Sag auch du wie 2 andere deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Syndax Pharmaceuticals Inc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | 2,13 % | -11,45 % | -13,69 % | 89,83 % | -7,74 % | -15,74 % | 34,27 % |
| Pacira Pharmaceuticals | 2,63 % | 3,54 % | 5,41 % | 25,13 % | 8,33 % | -28,22 % | -52,44 % |
| Supernus Pharmaceuticals | -2,96 % | -4,37 % | -2,96 % | 35,86 % | -8,37 % | 42,75 % | 79,09 % |
| Collegium Pharmaceutical Inc | -0,64 % | 0,65 % | -1,27 % | 18,18 % | -24,64 % | 57,58 % | 51,46 % |
Kommentare
News
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Key Points
- Interested in Syndax Pharmaceuticals, Inc.? Here are five stocks we like better.
- Syndax Pharmaceuticals is broadening its growth plan beyond Revuforj and Niktimvo, highlighting new
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
DAFNA Capital Management reported selling 222,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.89 million based on
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $8.18